Surface Oncology (DB:QSOA) - Hisse Senedi Fiyatı, Haberler ve Analizler

QSOA Stoklara Genel Bakış

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. Daha fazla detay

QSOA temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

1 yıldan az nakit akışı var

Geliri 1 milyon ABD dolarından az ( $0 )

Hissedarlar geçen yıl sulandırıldı

+ 2 daha fazla risk

Surface Oncology, Inc. Rakipler

4SC

DB:VSC

€51.9m

Medigene

XTRA:MDG1

€20.6m

Heidelberg Pharma

XTRA:HPHA

€106.7m

2invest

XTRA:2INV

€63.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Surface Oncology
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.99
52 Haftanın En Yüksek Seviyesi	US$1.41
52 Haftanın En Düşük Seviyesi	US$0.52
Beta	1.75
11 Aylık Değişim	16.19%
3 Aylık Değişim	36.16%
1 Yıllık Değişim	-27.10%
33 Yıllık Değişim	-82.41%
5 Yıllık Değişim	-88.77%
Halka arzdan bu yana değişim	-90.74%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	QSOA	DE Biotechs	DE Pazar
7D	-0.7%	0.8%	0.8%
1Y	-27.1%	-18.3%	8.6%

Getiri vs. Endüstri: QSOA geçen yıl % -18.3 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: QSOA geçen yıl % 8.6 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is QSOA's price volatile compared to industry and market?
QSOA volatility
QSOA Average Weekly Movement	12.0%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: QSOA hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: QSOA 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	35	Rob Ross	www.surfaceoncology.com

Surface Oncology, Inc. Temel Bilgiler Özeti

Surface Oncology'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
QSOA temel i̇stati̇sti̇kler
Piyasa değeri	€60.83m
Kazançlar(TTM)	-€86.46m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.7x

F/K Oranı

QSOA aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
QSOA gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$67.00m
Brüt Kâr	-US$67.00m
Diğer Giderler	US$25.50m
Kazançlar	-US$92.50m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.52
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

QSOA uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

QSOA Stoklara Genel Bakış

Risk Analizi

Surface Oncology, Inc. Rakipler

DB:VSC

€51.9m

XTRA:MDG1

€20.6m

XTRA:HPHA

€106.7m

XTRA:2INV

€63.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.43 loss in 2Q 2021)

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

First quarter 2022 earnings released: EPS: US$0.13 (vs US$0.37 loss in 1Q 2021)

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors

Revenue beats expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

New 90-day low: €5.95

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

New 90-day high: €9.20

Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

New 90-day high: €8.75

Surface Oncology, Inc. Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer

Revenue in line with expectations

Surface Oncology to Present Srf388 and Srf114 Preclinical Data At the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference

Surface Oncology, Inc. Announces Preclinical Data on SRF388

New 90-day high: €6.05

New 90-day high - €5.95

Earnings released

Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Value Index

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Surface Oncology, Inc. Temel Bilgiler Özeti

0.0x

-0.7x

Kazanç ve Gelir